Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future

Wang, Ting-Yao; George, Jacob; Zheng, Ming‐Hua

doi:10.21037/hbsn-21-352

Cited by 15 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Furthermore, an international panel of experts recently proposed a re-definition and re-classification of NAFLD, as metabolic dysfunction-associated fatty liver disease (MAFLD). [18][19][20][21] It has been proposed that the MAFLD definition may help facilitate a better understanding of metabolic factors involved in the development of NAFLD and T2DM, which are two closely interrelated pathological conditions. [18][19][20][21] The current definition of NAFLD requires the exclusion of significant alcohol consumption and other secondary causes of hepatic steatosis.…”

Section: Introductionmentioning

confidence: 99%

“…[18][19][20][21] It has been proposed that the MAFLD definition may help facilitate a better understanding of metabolic factors involved in the development of NAFLD and T2DM, which are two closely interrelated pathological conditions. [18][19][20][21] The current definition of NAFLD requires the exclusion of significant alcohol consumption and other secondary causes of hepatic steatosis. In contrast, the newly proposed definition of MAFLD is not an exclusionary diagnosis, and is based on the evidence of hepatic steatosis (as assessed by liver biopsy or imaging techniques) and the coexistence of at least one of the following three metabolic risk factors: (1) overweight or obesity; (2) established T2DM; or (3) metabolic dysregulation.…”

Section: Introductionmentioning

confidence: 99%

“…As early as 2016, the European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of Obesity societies strongly recommended screening for NAFLD in patients with established T2DM and screening for T2DM in patients with NAFLD [ 17 ]. Furthermore, an international panel of experts recently proposed a re-definition and re-classification of NAFLD, as metabolic dysfunction-associated fatty liver disease (MAFLD) [ 18 - 21 ]. It has been proposed that the MAFLD definition may help facilitate a better understanding of metabolic factors involved in the development of NAFLD and T2DM, which are two closely inter-related pathological conditions [ 18 - 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Miao¹,

Xu²,

Targher³

et al. 2022

Clin Mol Hepatol

Self Cite

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucoselowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Miao¹,

Xu²,

Targher³

et al. 2022

Clin Mol Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some international multicenter studies reported that patients with Sagliker syndrome have missense mutations in exons 1, 4, and 10 of the GNAS1 gene, but patients with CKD often have disorders of calcium and phosphorus metabolism, resulting in parathyroid hyperplasia and secondary parathyroid gland hyperfunction (5)(6)(7). The etiology of secondary hyperparathyroidism is complex.…”

Section: Discussionmentioning

confidence: 99%

Surgical treatment of secondary hyperparathyroidism combined with Sagliker syndrome caused by chronic renal failure: a case report

Pang¹,

Meng²

2022

Gland Surg

View full text Add to dashboard Cite

Background: Sagliker syndrome is caused by severe secondary hyperparathyroidism in hemodialysis patients with chronic renal failure. It is mainly manifested by disturbances of calcium and phosphorus metabolism and bone changes, which eventually lead to abnormal changes in facial appearance and morphology, seriously affecting the quality of life of patients. With the improvement of management mode and technology for hemodialysis in chronic renal failure, the incidence of severe secondary hyperparathyroidism related to hemodialysis is relatively reduced. Therefore, Sagliker syndrome is more rare. How to early identify and choose the appropriate treatment for Sagliker syndrome is particularly important.Case Description: A 34-year-old female patient with uremia, who underwent regular hemodialysis at the Blood Purification Center of Tianjin Third Central Hospital, developed Sagliker syndrome. The general data, clinical symptoms, height changes, biochemical indicators (serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, hemoglobin, and hematocrit), and parathyroid emission computerized tomography (ECT) were collected and analyzed. The patient had a history of hemodialysis with chronic renal failure for 6 years, and presented with bone pain for 2 years. Laboratory tests showed parathyroid hormone was 2,269 pg/mL and ECT showed 3 parathyroid hyperplasia. Finally, total parathyroidectomy and forearm transplantation were performed. The level of parathyroid hormone was significantly lower than that before the operation. On the first postoperative day, the level of parathyroid hormone decreased to 28.3 pg/mL. Four months later, the bone pain symptoms of the patient were significantly improved compared with those before the operation.Conclusions: Sagliker syndrome is a special syndrome in maintenance hemodialysis patients with refractory secondary hyperparathyroidism. Early monitoring and standardized treatment of secondary hyperparathyroidism may prevent the occurrence of Sagliker syndrome. Early identification and diagnosis of Sagliker syndrome and the choice of appropriate treatment will have an important impact for the prognosis.

show abstract

“…This is not possible when using the NAFLD definition, which requires the exclusion of all other causes of hepatic steatosis as a prerequisite for diagnosis. To date, the newly proposed definition of MAFLD has been accepted by many experts in the field, and by some pan-national societies; although debate is ongoing and there is not uniform agreement [ 8 , 9 ]. For some experts the change in terminology/definition from NAFLD to MAFLD seems premature and they suggest that such a change could also lead to confusion [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Zhou

Cai

Targher

et al. 2022

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

The newly proposed term “metabolic dysfunction-associated fatty liver disease” (MAFLD) is replacing the old term “non-alcoholic fatty liver disease” (NAFLD) in many global regions, because it better reflects the pathophysiology and cardiometabolic implications of this common liver disease. The proposed change in terminology from NAFLD to MAFLD is not simply a single-letter change in an acronym, since MAFLD is defined by a set of specific and positive diagnostic criteria. In particular, the MAFLD definition specifically incorporates within the classification recognized cardiovascular risk factors. Although convincing evidence supports a significant association between both NAFLD and MAFLD, with increased risk of CVD morbidity and mortality, neither NAFLD nor MAFLD have received sufficient attention from the Cardiology community. In fact, there is a paucity of scientific guidelines focusing on this common and burdensome liver disease from cardiovascular professional societies. This Perspective article discusses the rationale and clinical relevance for Cardiologists of the newly proposed MAFLD definition.

show abstract

Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future

Cited by 15 publications

References 15 publications

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Surgical treatment of secondary hyperparathyroidism combined with Sagliker syndrome caused by chronic renal failure: a case report

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Contact Info

Product

Resources

About